0.644 0.053 (8.97%) | 04-19 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.79 | 1-year : | 0.85 |
Resists | First : | 0.67 | Second : | 0.73 |
Pivot price | 0.64 | |||
Supports | First : | 0.59 | Second : | 0.49 |
MAs | MA(5) : | 0.61 | MA(20) : | 0.65 |
MA(100) : | 1.15 | MA(250) : | 1.82 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 15.1 | D(3) : | 8.6 |
RSI | RSI(14): 41.3 | |||
52-week | High : | 4.01 | Low : | 0.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DMTK ] has closed below upper band by 48.1%. Bollinger Bands are 68.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.69 - 0.7 | 0.7 - 0.7 |
Low: | 0.59 - 0.6 | 0.6 - 0.6 |
Close: | 0.64 - 0.64 | 0.64 - 0.65 |
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Thu, 18 Apr 2024
DermTech, Inc. (DMTK) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Movies UK
Thu, 18 Apr 2024
DermTech exploring strategic alternatives, cutting 56% of staff (NASDAQ:DMTK) - Seeking Alpha
Thu, 18 Apr 2024
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan - Business Wire
Wed, 17 Apr 2024
DermTech (NASDAQ:DMTK) Trading Down 0.9% - Defense World
Tue, 16 Apr 2024
DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37% - Yahoo Movies UK
Tue, 05 Mar 2024
Stephens cuts DermTech stock target to $1.50, keeps Equal Weight rating - Investing.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Diagnostics & Research
|
|
Shares Out | 35 (M) |
Shares Float | 33 (M) |
Held by Insiders | 4.2 (%) |
Held by Institutions | 21.2 (%) |
Shares Short | 3,160 (K) |
Shares Short P.Month | 3,150 (K) |
EPS | -3.09 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.65 |
Profit Margin | 0 % |
Operating Margin | -503.4 % |
Return on Assets (ttm) | -37.9 % |
Return on Equity (ttm) | -106.5 % |
Qtrly Rev. Growth | 31.1 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.44 |
EBITDA (p.s.) | -2.78 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -77 (M) |
Levered Free Cash Flow | -37 (M) |
PE Ratio | -0.21 |
PEG Ratio | 0 |
Price to Book value | 0.38 |
Price to Sales | 1.45 |
Price to Cash Flow | -0.29 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |